Making the CASE: Chemopreventive Use of Aspirin for Ovarian Cancer- Integrating Epidemiological Data to Evaluate Population Subgroups and Tumor Expression
Abstract
Objective: We hypothesize that the use of updated exposure information in cohort analyses will clarify and refine the ovarian cancer risk reduction associated with aspirin, that there are subgroups of women who will derive the most benefit from daily aspirin use with respect to ovarian cancer chemoprevention, and that aspirin will preferentially reduce risk for ovarian cancers dependent on the tumor immune microenvironment. Impact: The proposed research directly addresses the OCRP vision - to eliminate ovarian cancer, by addressing critical questions related to the prevention of ovarian cancer. This research also addresses OCRP research objectives related to cancer etiology, primary prevention, and understanding the mechanism(s) by which aspirin can prevent ovarian cancer. By leveraging and expanding upon the OC3 infrastructure through collection of updated exposure information and tumor tissue this well-powered investigation of aspirin use with ovarian cancer risk will address key questions needed to develop recommendations for aspirin-based chemoprevention. The identification of women who will derive the most benefit from aspirin for ovarian cancer chemoprevention will guide future clinical trials in high-risk populations. Further, our examination of potential biologic mechanisms using tumor tissue expression of COX-1/2 and immune/inflammation markers will help strengthen the causal link between daily aspirin use and ovarian cancer development and inform potential co-testing of immune-modulators and daily aspirin use to improve cancer prognosis and/or progression-free survival. Since aspiring generally has few side effects, the potential for public health impact is substantial, particularly if risk reductions are identified among women at moderate to high risk of ovarian cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1137212
Entities
People
- Britton Trabert
- Mary K Townsend
- Shelley S. Tworoger
Organizations
- Geneva Foundation